Amarin Corporation PLC
431 articles with Amarin Corporation PLC
-
Amarin Receives Positive CHMP Opinion for Icosapent Ethyl for Cardiovascular Risk Reduction
1/29/2021
Amarin Corporation plc (NASDAQ:AMRN) today announced that in response to Amarin’s Marketing Authorisation Application submission, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion,
-
Amarin Expands Cardiovascular Risk Reduction Patent Infringement Lawsuit to Include Health Care Insurance Provider
1/25/2021
Amarin Corporation plc (NASDAQ:AMRN), announced today an expansion of the scope of its VASCEPA® (icosapent ethyl) cardiovascular (CV) risk reduction patent infringement lawsuit against Hikma Pharmaceuticals PLC to include a health care insurance provider in the United States, Health Net, LLC.
-
Icosapent Ethyl Included in the Chinese Society of Cardiology (CSC) Updated Guidelines for Primary Prevention of Cardiovascular Diseases
1/21/2021
Amarin Corporation plc (NASDAQ:AMRN) today announced that the Chinese Society of Cardiology (CSC) has included icosapent ethyl in its updated Guidelines for Primary Prevention of Cardiovascular Diseases for 2021 as published in the Chinese Journal of Cardiovascular Diseases . The guideline authors include “icosapent ethyl 2 grams twice a day (as studied in REDUCE-IT ® ) as a treatment consideration to further lower ather
-
Amarin Provides Preliminary 2020 Results and 2021 Outlook
1/7/2021
Unaudited 2020 Total Net Revenue Estimated to Be Approximately $610 Million, an Increase of Approximately 42% Compared with 2019
-
Amarin to Present at 39th Annual J.P. Morgan Healthcare Conference
1/4/2021
Amarin Corporation plc announced that John F. Thero, Amarin's president and chief executive officer, is scheduled to present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 from 2:00 - 2:40 p.m. Eastern Time.
-
Amarin Highlights Multiple VASCEPA® (Icosapent Ethyl)-Related Scientific Findings Presented at National Lipid Association (NLA) Scientific Sessions 2020, Including First COVID-19 Clinical Results
12/14/2020
REDUCE-IT® EPA Encore Presentation reinforces Eicosapentaenoic Acid (EPA) levels from VASCEPA® (icosapent ethyl) strongly correlated to cardiovascular outcomes, more so than other biomarkers
-
Amarin Reports Encouraging Efficacy and Safety Results from Pilot Study Treating COVID-19 Infected Outpatients with VASCEPA® (Icosapent Ethyl) in Late Breaker Presentation at National Lipid Association (NLA) Scientific Sessions 2020
12/13/2020
VASCEPA COVID-19 CardioLink-9 Randomized Trial suggests improvement in patient-reported COVID-19 symptoms while achieving its primary endpoint by demonstrating a 25% reduction in high-sensitivity C-reactive protein (hsCRP) with encouraging short-term safety and tolerability data using VASCEPA loading dose
-
VASCEPA® (Icosapent Ethyl)-Related Scientific Findings to Be Presented at National Lipid Association (NLA) Scientific Sessions 2020
12/7/2020
Amarin-Supported Research and Analyses from Academic Collaborators to Be Featured in Two Late Breaker and Six e-Poster Presentations, Including Encore of REDUCE-IT® EPA, Primary Results of the VASCEPA COVID-19 CardioLink-9 Trial, and Mechanism of Action Insights
-
Amarin to Present at Piper Sandler’s 32nd Annual Healthcare Conference (Virtual)
11/24/2020
Amarin Corporation plc announced that John F. Thero, Amarin's president and chief executive officer, is scheduled to participate in a Fireside Chat at the Piper Sandler’s 32nd Annual Healthcare Conference taking place from December 1 - December 3, 2020.
-
Multiple New VASCEPA® (Icosapent Ethyl)-Related Scientific Findings Presented at American Heart Association’s Virtual Scientific Sessions 2020
11/18/2020
Findings further support the differentiated multifactorial mechanism of action of VASCEPA and its robust clinical effectiveness in reducing major adverse cardiovascular events (MACE) in studied high-risk patients
-
Amarin Corporation plc (NASDAQ:AMRN) today announced the presentation of REDUCE-IT® CABG at American Heart Association’s
11/13/2020
VASCEPA ® , compared with placebo, significantly reduced primary composite first and total major adverse cardiovascular events ( MACE ) in post hoc exploratory analyses of patients with a history of CABG by 2 4% and 3 6 %, respectively, and key secondary composite first hard MACE, comprised of heart attacks, stroke and cardiovascular death, by 3 1 % Administration of VASCEPA resulted in robust absolute risk reductions of 6 . 2 % and 6 . 0 % and numbers needed to tr
-
Amarin to Present at the Stifel 2020 Virtual Healthcare and Jefferies Virtual London Healthcare Conferences
11/11/2020
Amarin Corporation plc (NASDAQ:AMRN) today announced that John F. Thero, Amarin's president and chief executive officer, is scheduled to present general company updates at the following investor conferences scheduled in November: Stifel 2020 Virtual Healthcare conference on Monday, November 16, 2020 at 8:40 a.m. Eastern Time (ET) Jefferies Virtual London Healthcare conference on Thursday, November 19, 2020 at 9:40 a.m
-
Amarin Reports Third Quarter 2020 Financial Results and Provides Business Update
11/5/2020
Total Revenue Increased 39% in Third Quarter 2020 and 56% in First Nine Months of 2020 Compared toSame Periods of 2019 Despite COVID-19 Headwinds
-
VASCEPA® (Icosapent Ethyl) Found to Significantly Reduce Cardiovascular Events in Patients with Compromised Renal Function at Baseline in Prespecified and Post Hoc Subgroup Analyses of Landmark REDUCE-IT® Study Presented at ASN Kidney Week 2020
10/26/2020
Patients with decreased renal function prior to treatment with VASCEPA or placebo had higher rates of cardiovascular events than the overall population studied in REDUCE-IT
-
Amarin to Report Third Quarter 2020 Results and Host Conference Call on November 5, 2020
10/19/2020
Amarin Corporation plc announced that it will host a conference call with members of Amarin senior management to discuss the company's third quarter 2020 financial results and provide an operational update on Thursday, November 5, 2020, at 7:30 a.m. ET.
-
VASCEPA® (Icosapent Ethyl) Found to Significantly Reduce Ischemic Events in Patients with Prior Percutaneous Coronary Intervention (PCI) in Post Hoc Subgroup Analyses of Landmark REDUCE-IT® Study Presented at TCT Connect 2020
10/15/2020
Consistent and robust benefit seen in post hoc exploratory analyses of patients with a history of PCI across the hierarchy of endpoints prespecified for the full study cohort
-
Latest Research Evaluating VASCEPA® (Icosapent Ethyl) Mechanisms of Action Presented at European Atherosclerosis Society (EAS) Congress 2020
10/5/2020
Data presented provides additional insight into potential mechanisms by which VASCEPA lowers cardiovascular risk
-
Amarin to Present at the 2020 Cantor Virtual Global Healthcare Conference
9/9/2020
Amarin Corporation plc announced that John F. Thero, Amarin's president and chief executive officer, is scheduled to present at the 2020 Cantor Virtual Global Healthcare Conference on Wednesday, September 16, 2020 from 11:20 - 11:50 a.m. Eastern Time.
-
Shares of Amarin Corporation are down more than 3% in premarket trading after the company reported Thursday that a panel of three judges from the U.S. Court of Appeals upheld a lower court’s ruling that paved the way for generic competition for the company’s heart disease drug, Vascepa.
-
Amarin Provides Update Following Ruling in VASCEPA® ANDA Patent Litigation
9/3/2020
Amarin Corporation plc (NASDAQ:AMRN) today provided an update following the decision by the U.S. Court of Appeals for the Federal Circuit in the company’s ongoing patent litigation. The Court upheld the March ruling by the U.S. District Court for the District of Nevada in favor of two generic companies in connection with their abbreviated new drug applications, or ANDAs, related to Amarin’s VASCEPA® (icosapent ethyl) cap